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Aim: To compare the ability of both terpesomes (TPs) and leciplex (LPs) loaded moxiflox
acin hydrochloride (MOX) for enhancing ocular drug conveyance.
Methods: Two separate 21.31 full-factorial trials were established to determine the influence
of multiple variables upon nanovesicles properties and select the optimized formulae using
Design Expert® software. The thin-film hydration method was used to formulate TPs, while
the single-step procedure was used for LPs. All formulae were characterized for their
entrapment efficiency percent (EE%), particle size distribution (PS), polydispersity index
(PDI), and zeta potential (ZP). Then, the optimized formulae were selected, evaluated, and
compared for additional assessments.
Results: The optimized formulae TP4 and LP1 showed EE% of 84.14±0.21 and 78.47
±0.17%, PS of 578.65±5.65 and 102.41±3.39 nm, PDI of 0.56±0.04 and 0.28±0.01, ZP of
−12.50±0.30 and 32.50±0.50 mV, respectively. Further, LP1 showed enhanced corneal permea
tion across cow cornea compared to MOX solution and TP4. Besides, confocal laser scanning
microscopy assessment viewed valuable infiltration from the fluoro-labeled LP through corneal
layers compared to TP. LP1 showed spherical morphology and, its ability to adhere to mucus
membranes was justified. Further, LP1 showed superiority over MOX solution in biofilm
inhibition and eradication in addition to the treatment of infected mice with methicillinresistant Staphylococcus aureus without any inflammatory response. Finally, the histopatholo
gical study verified the harmlessness and biocompatibility of the assembled LPs.
Conclusion: The gained outcomes confirmed the capability of utilizing LPs as a successful
nanovesicle for the ocular conveyance of MOX over TPs and MOX solution.
Keywords: biofilm, confocal laser microscope, moxifloxacin hydrochloride, MRSA,
leciplex, ocular drug conveyance, terpesomes
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Several severe complications such as corneal damage, vision loss, or even complete
blindness may occur in case of inadequate treatment of bacterial keratitis. Corneal
infections are complications of extended wearing of contact lenses, sutures, and
glaucoma tubes. According to microbiologists, pathogens can build biofilms on eye
surfaces, leading to difficult bacterial eradication due to biofilm drug resistance.1
Staphylococcus aureus corneal infections represent a threat to visual acuity. One
of the critical challenges in treating Staphylococcal corneal infections is the
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emergence of antibiotic resistance, in addition, most of the
pathogenic strains are multi-drug resistant. Methicillinresistant Staphylococcus aureus (MRSA) is considered
a community and hospital-gained virulent pathogen asso
ciated with increasing persistent and complicated eye
infections. Therefore, there is a demanding urge for the
development of alternative therapeutic systems with
improved antimicrobial activity.2
Moxifloxacin Hydrochloride (MOX) is an antimicro
bial of low toxicity and has an effect against gram (+ve),
and gram (-ve) bacteria.3 MOX is either given as an
intracameral injection or topically. However, the intracam
eral injection may cause corneal endothelial toxicity and
toxic anterior segment syndrome. On the other hand, topi
cal administration of MOX solutions suffers from low
ocular bioavailability (1–7%) due to the short residence
time, superior lacrimal drainage, and inferior infiltration
through the corneal barriers. The human cornea is com
posed of three distinct layers lipophilic epithelium, hydro
philic stroma, and endothelium. Endothelial cells are the
major components of the ocular blood barriers found in the
uvea, and these cells prevent the delivery of hydrophilic
drugs through the aqueous humor. For that reason, drugs
that have a high log P value (2–4) can permeate through
the cornea easily. Therefore, a promising approach with
high residence time and permeation via cornea is desired
to conquer the short washout time and enhance the inade
quate drug permeation through the cornea.4
MOX is characterized by high aqueous solubility so its
delivery through nanocarriers is a good choice.
Accordingly, encapsulation of MOX into lipid-based nano
carrier would provide sustained release which led to
a reduction in the effective therapeutic dose and dosedependent shortcomings of the drug.5
Terpesomes (TPs) are terpenes containing vesicles, pre
viously described by Albash et al, to treat ocular
candidiasis.6 Terpenes are naturally occurring substances
derived from essential oils and made up of several isoprene
units.6 Terpenes are not only well-known penetration enhan
cers, but they also possess both antimicrobial and antifungal
activities as a consequence of their residence in the lipo
philic entities of the cell bilayer; which allows constituents
of essential oils to be delivered to the inner of the cell,
leading to cytoplasmic infiltration, and cell death.7
On the other hand, Leciplex is a new vesicular nanosys
tem based on the combination of negatively charged phos
pholipids, cationic surfactants, and Transcutol®.8 Leciplex
(LPs) were previously reported by Hassan et al for the
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treatment of glaucoma and concluded that LPs improve
the ocular bioavailability and transcorneal permeability of
Carvedilol.8 The privilege of LPs over conventional sys
tems is their ability to be fabricated via a single-procedure
fabrication that provides nanosized vesicular systems via
simple blending.8,9
Based on the effective utilization of both TPs (negatively
charged vesicles) and LPs (positively charged vesicles) as
successful ocular drug delivery systems, the present study
suggests that both carriers could successfully deliver MOX.
Therefore, two separate 21.31 full factorial designs utilizing
the Design Expert® program were employed to investigate
the impact of different variables on TPs and LPs and com
pare their influence. Phospholipid (PC) concentration (X1)
and terpene type (X2) were selected as independent factors
for TPs design while surfactant (SAA) type (X1) and PC:
(SAA) molar ratio (X2) were selected as independent factors
for LPs design. On the other hand, entrapment
efficiency percent (EE%; Y1), particle size (PS; Y2), poly
dispersity index (PDI; Y3), and zeta potential (ZP; Y4) were
chosen as dependent responses. The best-achieved formulae
were subjected to further ex-vivo permeation study and con
focal laser scanning microscopy examination. After that, the
nanovesicles that achieved the highest permeation and illu
strated the highest fluorescence intensity were subjected to
additional in-vitro and in-vivo antibacterial assessments.

Materials
Moxifloxacin hydrochloride (MOX) was donated from
Kahira Pharmaceutical Co. (Cairo, Egypt). L-α phosphati
dylcholine from egg yolk, cetyltrimethylammonium bro
mide (CTAB), dimethyldidodecylammonium bromide
(DDAB), fluorescein diacetate (FDA), and mucin from
porcine stomach type II were purchased from SigmaAldrich Chemical Co. (St. Louis, MO, USA). Fenchone,
cineole, and limonene were purchased from Alfa Aesar
(GmbH, Germany). Diethylene glycol monoethyl ether
(Transcutol® HP) was obtained from Gattefosse (Cedex,
France). Acetonitrile and methanol (HPLC) were pur
chased from Merck (Darmstadt, Germany).

Methods
Preparation of MOX-Loaded TPs
TPs were prepared by varying both terpenes type and PC
(soy phosphatidylcholine) concentration using the thinfilm hydration method (Table 1). At first, PC and terpenes
were solubilized into 10 mL methanol in a round flask. By
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Table 1 Full Factorial Design for the Optimization of MOXLoaded TPs and LPs
Factors (Independent
Variables) For TPs Design

Levels

X1: PC concentration

1%

3%

X2: Terpene type

Fenchone

Factors (Independent Variables)

Cineole

Limonene

EE ð%Þ ¼

Levels

for LPs Design
X1: SAA type
X2: PC: SAA molar ratio

CTAB
1:1

Responses (Dependent

DDAB
1:2

1:5

Constraints

Variables)
Y1: EE (%)

Maximize

Y2: PS (nm)

Minimize

Y3: PDI

Minimize

Y4: ZP (mV)

Maximize

immersed in 100 mL of distilled water magnetically stirred at
60 rpm.14 At selected time-points, aliquots were removed, and
MOX was spectrophotometrically assayed at 288 nm employ
ing a UV-Vis spectrophotometer (UV-1650; Shimadzu Corp.,
Kyoto, Japan) until a constant concentration was obtained. EE
% was then calculated by the following equation:

Abbreviations: EE%, entrapment efficiency percent; CTAB, cetrimonium bromide;
DDAB, didodecyldimethylammonium bromide; MOX, moxifloxacin hydrochloride;
PS, particle size; PDI, polydispersity index; PC, phospholipid; ZP, zeta potential; LPs,
leciplex; TPs, terpesomes.

maintaining pressure under vacuum for 30 min, methanol
was evaporated at 60°C using a rotatory evaporator
(Rotavapor, Heidolph VV 2000, Burladingen, Germany)
at 90 rpm to form a thin film of TPs. The formed film
was hydrated with 10 mL water containing 50 mg MOX at
60 °C. For more efficient film hydration, glass beads were
used during the hydration step for 45 min.10

Preparation of MOX-Loaded LPs
A simple single-step procedure was used in preparing LPs
by varying both PC: SAA molar ratio and type of cationic
SAA (Table 1). At first, PC and cationic SAA were dis
solved in Transcutol® HP (0.5 mL) and heated at 70°C in
a water-bath after that 50 mg of MOX dissolved in 9.5 mL
water and kept at 70°C was added with continuous mixing
till homogeneous nano-dispersion was obtained.8,11,12

Characterization and Optimization of
MOX-Loaded TPs and LPs

Total MOX amount Diffused MOX
� 100
Total MOX amount
(1)

Each evaluation is the average of three individual experi
ment± SD.

Determination of PS, PDI, and ZP
PS, PDI, and ZP of the fabricated formulations were assessed
through the light scattering approach at 25°C via Malvern
Zetasizer (Malvern Instruments Ltd., Malvern, UK). The
assessments were fulfilled after appropriate dilution.10,11 All
evaluations were assessed in three trials±SD.

Optimization of MOX Loaded TPs and
LPs Formulations Using Full Factorial
Designs
A 21.31 factorial experiment was used to investigate the
influence of multiple factors in fabricating TPs and LPs in
two separate designs via Design Expert® software version
11 (Stat Ease, Inc., Minneapolis, MN, USA). In the first
experimental design, two factors were inspected for TPs
formulation: one factor with two levels (X1: PC concen
tration) and another factor with three levels (X2: terpene
type). While in the other design, for LPs formulation, the
two evaluated factors were (X1: cationic SAA type) at two
levels and (X2: PC: SAA molar ratio) at three levels. The
EE% (Y1), PS (Y2), PDI (Y3), and ZP (Y4) were used as
dependent variables in both designs (Table 1).

Selecting the Optimized MOX-TPs and
MOX-LPs Formulae
The selection of optimized formulae relied on the desir
ability tool, which allowed the analysis of each response
simultaneously. The principle for choosing the optimized
formulae was producing the least PS and PDI and the
highest EE% and ZP.15

Determination of EE%
EE% of both TPs and LPs was calculated via the dialysis
method for separating the non-entrapped MOX from the
nanovesicles.13 1mL of the MOX-loaded nanovesicles was
placed in a dialysis bag (M.W of 12,000 Dalton) and then
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Ex-vivo Permeation Studies
A corneal permeation study was performed through
a Franz diffusion cell with a surface area of 0.785 cm2.
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Precisely, 1mL of MOX solution, the optimized TP, and
optimized LP, equal to 5 mg of MOX, were transferred in
the donor cells. The receptor chamber was loaded with
12 mL of phosphate buffer saline (pH 7.4) at 37 °C. At
a definite time, 0.5 mL of receiver media was removed,
and an exact volume of fresh media was added into the
receiver chamber. The samples were analyzed by using
HPLC, where a C18 column was used with a mobile
phase of (water + triethylamine (2%, v/v)): acetonitrile =
90:10 (v/v%); the pH of water phase being adjusted with
phosphoric acid to 6.0. The flow rate of the mobile phase
was 1.5 mL/min, and UV detection at 290 nm was
employed. The column was adjusted at 45 °C. Method
validation parameters indicate linear dynamic range 0.2–
2.0 μg/mL with LOQ ca. 0.20 μg/mL and LOD ca. 0.05
μg/mL for all analytes.16 The permeation flux (Jmax) at 6
h and the enhancement ratio (ER) were calculated. The
experiment was performed in three trials ± SD. Statistical
significance was inspected via one-way ANOVA by
SPSS® software 22.0. The post-hoc test was performed
utilizing Tukey’s honest significant difference (HSD) test.

Confocal Laser Scanning Microscopy Study (CLSM)
To trace the permeation of the optimized TP and LP
formulae through different corneal layers, the formulae
were prepared as previously described, except that the
drug was replaced with FDA at 1% (w/v).17 Cow cornea
was mounted in diffusion chambers with the previous
aspects of the ex-vivo permeation study. To mimic
the administration of optimized formulae in contact with
the eye surface, FDA-loaded nanovesicles were applied on
the corneal surface and remained for 6 h. Longitudinal
sections kept in paraffin wax and cut into sections using
a microtome (Rotary Leica RM2245; Leica Biosystems,
Wetzlar, Germany) were observed for fluorescence in the
corneal tissues. The slides were visualized employing an
inverted microscope (LSM 710; Carl Zeiss, Oberkochen,
Germany). The excitation and emission wavelengths of the
FDA were λmax 497 nm and λmax 516 nm, respectively.
The cornea was optically scanned under a 40× objective
lens (EC-Plan Neofluar 63x/01.40 Oil DICM27). Confocal
images were supplied by LSM Image Browser software,
release 4.2 (Carl Zeiss Microimaging GmbH, Jena,
Germany).18 For comparative assessment between the
optimized TP and the optimized LP, several sections
were selected in corneal tissues and, the intensity of light
was compared and analyzed. Statistical significance was
assessed by Student’s t-test employing SPSS® software
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22.0. Difference at P≥0.05 was regarded as significant.
The experiment was performed in three trials ± SD.

Morphology
Based on ex-vivo studies the morphology was assessed for
the selected formula via a transmission electron micro
scope (TEM) (JEM-1230, Joel, Tokyo, Japan). The diluted
formula was placed on the top of a carbon-coated grid and
negatively stained with a 1% phosphotungstic acid, then
dried for visualization.19

Stability Study
The physical stability of the selected formula was investi
gated to monitor the extent of vesicles’ growth, drug
leakage, or any other physical change. The selected for
mula was kept at room temperature for three months and
then assessed by comparing the EE%, PS, PDI and, ZP of
the stored formula with the fresh vesicles. Besides, the
system was visually observed for any sedimentation.20

pH Measurement
To test the selected formula’s ocular tolerance, the pH was
measured using a calibrated potentiometer (Inolab pH 720,
WTW, Germany) at ambient temperature. The results were
the mean of triplicate trials ± SD.21

Evaluation of Mucoadhesion Properties of
Nanovesicles
The mucoadhesive properties of the selected formula were
evaluated where 1% w/v of porcine mucin was mixed with
the same quantity of the selected formula in a dropwise
manner under stirring. The stirring was conducted for an
additional five minutes, and the mixture was allowed to
equilibrate overnight at room temperature. The surface
charge of mucin particles and the charge of mucoadhesive
nanovesicles in the presence of mucin were evaluated by
zetasizer.22

Determination of Minimum Inhibitory
Concentration (MIC)
The antibacterial potency of the selected formula and
MOX solution was assessed against MRSA USA300.
Accordingly, MIC of both was assessed by the broth
microdilution approach in agreement with the guidelines
of the Clinical and Laboratory Standards Institute. 150 μL
of double efficacy Mueller Hinton broth was pipetted into
each well of a sterile 96-well microplate, and 150 μL of
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the selected formula/solution (5 μg/mL) was after that
dropped into the first well of each column.23,24
Subsequent two-fold dilutions were performed across the
microplates (2.5–0.0195 μg/mL). Bacterial inoculum
(MRSA USA300) was then added to the wells, and each
well was inoculated with 15 μL of bacterial suspension
(108 CFU/mL). One column was utilized as a sterility
control (neither bacterial suspension nor selected formula
was added). In addition, another column was employed as
a growth control (inoculated with bacterial suspension
without adding the test formula). The microplates were
incubated under aerobic conditions at 37°C for 24 h, and
then the MIC was recorded. The MIC was known as the
lowest concentration with no detectable bacterial growth
(no turbidity). The experiment was repeated in three
trials ±SD.

Effect of the Selected Formula on the
Anti-Biofilm Activity of MOX
The anti-biofilm activity of the selected formula was com
pared to that of the MOX solution.

Biofilm Inhibition Assay
The selected formula and MOX solution were tested at
concentrations below the MIC (MIC/2, MIC/4, MIC/8,
MIC/16, MIC/32, MIC/64, MIC/128, and MIC/256). The
biofilm inhibition assessment was done as mentioned
before.25 Precisely, the MRSA USA300 suspension (108
CFU/mL) in tryptic soy broth (TSB) was added in a flatbottom 96-well ELISA plate (200 μL/well). Different con
centrations of the selected formula/solution were added to
the loaded wells (20 μL/well). Nothing was added to the
control wells (untreated, 100% reference measurements).
The plates were then incubated at 37°C for 24 h at
static aerobic conditions. After incubation, the grown cul
tures’ optical density (OD600) was assessed by
a spectrophotometric plate reader (Biotek, Synergy 2,
USA). The formed biofilms were quantified as follows;
wells were washed with saline then dried. The dried bio
film was then stained with crystal violet (0.1% w/v, 200
μL/well) for 30 minutes at room temperature. The wells
were then washed three times with distilled water and
dried. The crystal violet in the stained biofilm was liquified
by adding absolute ethanol (200 μL/well) and incubating
for 20 minutes at 4°C (to minimize evaporation). The
OD550 of the crystal violet solutions was assessed by
spectrophotometric plate reader and divided by OD600 of
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the grown cultures for normalization. The biofilm inhibi
tion % was calculated by the following equation:25
Biofilm inhibition % ¼

OD Control OD Test
� 100
OD Control
(2)

Biofilm Eradication Assay
The ability of the selected formula and MOX solution to
eradicate the previously established MRSA USA300 biofilm
was investigated. The selected formula and MOX solution
were tested at concentrations below the MIC (MIC/2, MIC/4,
MIC/8, MIC/16, MIC/32, MIC/64, MIC/128, and MIC/256).
The experiment was performed as described before.25 MRSA
USA300 suspension in TSB broth (106 CFU/mL) was loaded
in a flat-bottom 96-well enzyme-linked immune sorbent
assay (ELISA) plate (200 μL/well) and incubated at 37°C
for 24 h in static aerobic status. After incubation, OD600 of
the grown cultures was assessed by an automated spectro
photometric plate reader (Biotek, Synergy 2, USA). The
wells were carefully evacuated by aspiration. Several con
centrations of the selected formula/solution were prepared in
fresh TSB broth and were added to the biofilm plate (200 μL/
well). Nothing was added to the biofilm control wells
(untreated biofilm, 100% reference value). The plate was
then re-incubated at 37°C for 24 h. After the treatment
period, crystal violet staining and measurement were per
formed as described previously. The experiment was
repeated three independent times. The biofilm eradication
% was calculated by the following equation:25
Biofilm eradication % ¼

OD Control OD Test
� 100
OD Control
(3)

In-vivo Assessment of the Selected
Formula
Murine MRSA Corneal Infection Model and
Histopathologic Evaluation
All the animal care and experiments in this assessment
were authorized via the Research Ethics Committee of the
Faculty of Pharmacy, Cairo University (Approval no. MI
2796), adhering to the “Guide for the Care and Use of
Laboratory Animals” declared via the Institute of
Laboratory Animal Research (Washington, DC, USA).
The murine model of MRSA corneal infection was con
ducted as described before with slight modifications.26
Twenty-eight male BALB/C mice (7 weeks old weighing
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150–200 gm) were gained from the Modern Veterinary
Office for Laboratory Animals, Cairo, Egypt. Standard
commercial food and tap water ad libitum were provided
to the mice, and they were permitted to habituate for seven
days (25 ± 2 °C, 12:12 h light-dark) before establishing the
experiment. All the eyes were first inspected with a slit
lamp. Only animals without any signs of ocular inflamma
tion were included in the study. The mice were anesthe
tized with ketamine (70 mg/kg i.p.), and 0.5%
proparacaine was applied to the eyes of each mouse. A 30gauge needle was used to inoculate each eye with only one
colony of MRSA USA300; 3–4 scratches were made
through the cornea taking care not to infiltrate the super
ficial stroma. The scratches were then inoculated with a 5
μL of MRSA USA300 suspension (7×108 CFU) employ
ing a micropipette; after that, the eyelids were closed
manually for 15 seconds. Then, mice were divided into
two groups (fourteen mice per group, n=14) after infec
tion. One group was treated with the selected formula,
while the other was treated with the MOX solution.
Treatments were administered in 5 μL aliquots to the
right eye (of each mouse) twice per day, beginning 24
h post-infection and ending 72 h post-infection. The left
eye of each mouse did not receive treatment and acted as
the negative control. At the end of the experiment, the
animals were euthanized, and the whole eyes were dis
sected. Eight mice from each group (n=8) were employed
to assess the number of viable Staphylococcus aureus
colonies. Each eye was homogenized in 0.5 mL saline
(homogenizer, DAIHAN-scientific-pacific lab). The homo
genates were diluted ten folds and plated for the viable
aerobic count on mannitol salt agar (MSA), then incubated
at 37 °C for 24 h. The colony-forming units (CFU) were
counted, and the results of treated groups (right eyes) were
correlated to each other and to that of the untreated nega
tive controls (left eyes). Three mice from each group (n=3)
were utilized for the histopathology examination as
described before. The whole eyes were fixed in formalin
saline solution (10% v/v).27 After fixation, the eyes were
bisected, and the specimens were dehydrated by alcohol,
fixed in melted paraffin. Microtome was employed to
arrange thin sections (2 mm), deparaffinized and pigmen
ted by hematoxylin and eosin. A light microscope
(DMS1000 B; Leica, UK) was utilized to inspect samples.

Assessment of Serum Inflammatory Biomarkers
Finally, after performing the in-vivo experiment, three
mice from each group received anesthesia, and blood
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samples were collected into tubes via retro-orbital punc
ture for assessment of high-sensitivity C-reactive protein
(hs-CRP) and interleukin- 1 beta (IL-1Beta) employing
enzyme-linked immunosorbent assay (ELISA) according
to the manufacturer’s commands.28 The assay procedure
was conducted by measuring the absorbance of the yellow
color at 450 nm. The sample concentration was deter
mined from the corresponding standard curve.22

Results and Discussion
Factorial Design Optimization
Preliminary trials were carried out to detect the promising
ranges of the independent variables. Independent variables
that were studied for TPs: PC concentration (X1) and
terpene type (X2) while independent variables that were
studied for LPs: cationic SAA type (X1) and PC: SAA
molar ratio (X2). EE% (Y1), PS (Y2), PDI (Y3), and ZP
(Y4) were selected as dependent variables. Noticing the
design analysis values in Table 2, the model selected was
two-factor interaction. It was noted that the predicted R2
Table 2 Output Data of the Two Full Factorial Designs (21.31)
Analysis of TP and LP Formulations and the Predicted and
Observed Values for the Selected TP (TP4) and LP (LP1)
Responses

EE%

PS
(nm)

PDI

ZP
(mV)

Adequate precision (TP)

33.46

10.96

6.08

26.75

Adjusted R2 (TP)

0.98

0.88

0.64

0.98

Predicted R2 (TP)

0.97

0.74

0.21

0.96

Significant factors (TP)

X1, X2

X1, X2

X2

X 1 , X2

Predicted value of selected

84.18

578.65

0.56

−12.50

Observed value of selected
formula (TP4)

84.14

578.65

0.56

−12.50

Adequate precision (LP)

40.77

41.35

25.51

12.06

Adjusted R2 (LP)

0.99

0.99

0.97

0.92

0.98

0.98

0.95

0.84

Significant factors (LP)

X1, X2

X1, X2

X2

X 1 , X2

Predicted value of selected

78.47

102.41

0.28

32.50

78.47

102.41

0.28

32.50

formula (TP4)

2

Predicted R (LP)

formula (LP1)
Observed value of selected
formula (LP1)
Abbreviations: EE%, entrapment efficiency percentage; PS, particle size; PDI,
polydispersity index; TP, terpesomes; LP, leciplex, and ZP; zeta potential.
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values were in reasonable agreement with the adjusted R2
in all responses except PDI. The adequate precision
greater than 4 is desirable,18 which was recognized in all
responses as shown in Table 2.

Effect of Formulation Variables on the EE%
The significance of the independent variables, X1 and X2,
on the EE% of MOX in both TPs and LPs is illustrated in
Table 2. It is also graphically presented as threedimensional (3-D) surface plots in Figures (1A and 2A).
EE% of MOX within TPs formulations ranged from 60.45
±1.05 to 85.96±0.10%, as shown in Table 3. The results
showed that the increase in PC concentration (X1) led to
an increase in EE% significantly (p = 0.0003). These
results might be related to the surface-active properties
of PC that might enhance the formation of strong coherent
layers around TPs and hence might reduce the leakage of
MOX.29 Moreover, a higher viscosity would be obtained
upon using higher PC concentration which might mini
mize the external diffusion of MOX.10
Additionally, terpene type (X2) had a significant influence
(p < 0.0001) on EE%. It was found that TPs with the highest
EE% were fabricated with fenchone followed by cineole then
by limonene. These results could be ascribed to the

Albash et al

lipophilicity of the employed terpenes as revealed by their
log P values log P = 2.13, 2.82, and 4.83 for fenchone,
cineole, and limonene, respectively.29 Previous studies
revealed that higher entrapment efficiency for the lipophilic
drug as dapsone and finasteride was obtained using a terpene
with high lipophilicity.30,31 On the contrary, in this study
results, can be inferred as MOX being a hydrophilic drug,
has higher entrapment efficiency when combined with fench
one having lower lipophilicity. These findings agree with
Vidya et al, who found that the EE% of hydrophilic drug
anastrozole increased in the presence of fenchone compared
to more lipophilic terpene.31 Also, the electrostatic attraction
between the amino group of MOX, positively charged at pH
7.4, and the carbonyl group in fenchone could also contribute
to a higher EE% of MOX in the fenchone based formulae.32
For LPs formulations, EE% ranged from 74.02±0.79 to
96.85±0.21%, as shown in Table 3. SAA type (X1) had
a significant influence (p < 0.0001) on EE% of LPs, in
which the highest EE% was found in LPs with CTAB rather
than DDAB. These results could be attributed to the differ
ence in the lipophilicity between CTAB and DDAB, where
CTAB with the lowest lipophilicity (log P=8) could help in
entrapping MOX (hydrophilic drug) more than DDAB with
higher lipophilicity (log P=11.8).33 The results also indicated

Figure 1 Response 3D plots for the effect of PC ratio (X1) and terpene type (X2) on (A) EE%, (B) PS, (C) PDI and (D) ZP of MOX loaded TPs.
Abbreviations: EE%, entrapment efficiency percent; PS, particle size; PDI, polydispersity index; ZP, zeta potential; MOX, moxifloxacin hydrochloride; TP, terpesomes.
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Figure 2 Response 3D plots for the effect of SAA type (X1) and PC: SAA molar ratio (X2) on (A) EE%, (B) PS, (C) PDI and (D) ZP of MOX loaded LPs.
Abbreviations: EE%, entrapment efficiency percent; PS, particle size; PDI, polydispersity index; ZP, zeta potential; SAA, surfactant; MOX, moxifloxacin hydrochloride; LP, leciplex.

that PC: SAA molar ratio (X2) significantly affected EE% (p
< 0.0001) by a direct positive relationship which may be due
to PC solubilization by SAA, leading to drug leakage from

LPs when they have the same molar ratio but when PC
increased, SAA will not be enough to solubilize PC leading
to the development of the tight bilayers and EE% increased.9

Table 3 Experimental Runs, Independent Variables, and Measured Response of the 21.31 Full Factorial Experimental Design of MOX
Loaded TPs and LPs.
Formulation Code of

PC Concentration

Terpene Type (X2)

EE%

PS (nm)

PDI

ZP (mV)

1%
3%

Fenchone
Fenchone

82.32±0.80
85.96±0.10

711.10±61.10
793.65±8.85

0.65±0.03
0.72±0.01

−10.30±0.50
−11.82±0.50

TP3

1%

Cineole

79.70±0.06

560.10±1.30

0.58±0.01

−4.31±0.06

TP4
TP5

3%
1%

Cineole
Limonene

84.14±0.21
60.45±1.05

578.65±5.65
515.00±5.00

0.56±0.04
0.59±0.027

−12.50±0.30
−3.87±0.08

TP6

3%

Limonene

66.22±1.29

568.35±1.15

0.61±0.07

−12.05±0.15

SAA Type (X1)

PC: SAA Molar Ratio

EE%

PS (nm)

PDI

ZP (mV)

TPs

(X1)

TP1
TP2

Formulation Code of
LPs

(X2)

LP1

CTAB

1:1

78.47±0.17

102.41±3.39

0.28±0.01

32.50±0.50

LP2

DDAB

1:1

74.02±0.79

117.75±0.95

0.26±0.005

32.10±0.70

LP3
LP4

CTAB
DDAB

2:1
2:1

86.50±0.85
74.87±0.66

131.21±1.21
145.31±0.66

0.36±0.02
0.34±0.0005

32.20±2.20
42.80±0.80

LP5

CTAB

5:1

96.85±0.21

161.05±1.05

0.46±0.005

35.00±1.00

LP6

DDAB

5:1

90.20±0.07

169.35±0.55

0.55±0.01

45.35±0.15

Note: Data represented as mean ± SD (n=3).
Abbreviations: EE%, entrapment efficiency percentage; LP, leciplex; MOX, moxifloxacin hydrochloride; PC, phospholipid; PS, particle size; PDI, polydispersity index; TP,
terpesomes, and ZP, zeta potential.
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Effect of Formulation Variables on the PS
PS of TPs ranged from 515.00±5.00 to 793.65±8.85 nm, as
displayed in Table 3 and Figure 1B. ANOVA results pro
vide that both X1 and X2 had a significant influence on the
PS of the prepared TPs. PC concentration (X1) positively
impacted the PS (p = 0.0477), where increasing PC con
centration resulted in larger PS of the prepared TPs. These
findings agree with the results of EE%, where increasing
PC concentration resulted in a higher entrapment of MOX
in TPs. Regarding terpene type (X2), an inverse relation
was found between PS and the lipophilicity of the used
terpenes at a p-value = 0.0003. TPs prepared using fench
one had the largest PS compared to other TPs prepared
with other terpenes. These results may be due to the low
lipophilicity of fenchone, resulting in a high repulsion
force between the hydrophilic terpene and lipophilic nat
ure of the vesicular system. Correspondingly, TPs pre
pared using limonene had the smallest PS due to the
highest lipophilicity of limonene.10
In addition, PS of LPs formulations ranged from 102.41
±3.39 to 169.35±0.55 nm, as shown in Table 3 and
Figure 2B. Both X1 and X2 had a significant effect on the
PS of the LPs, at a p-value < 0.0001. Considering X1 (SAA
type), smaller vesicles were obtained by single chained
cationic surfactant CTAB compared to those formulated by
double-chained surfactant DDAB, similar results were found
by Date et al.12 For X2 (PC: SAA molar ratio), larger
vesicles were obtained at high PC: SAA molar ratio. These
results could be due to that at a high PC level, the amount of
SAA will be not enough to lower the interfacial tension
leading to the formation of larger LPs.34

Effect of Formulation Variables on the
PDI
The values of PDI ranged between 0.56±0.04 and 0.72
±0.01 for all TPs formulations, as shown in Table 3 and
Figure 1C. These results indicate that the prepared TPs
were polydisperse but within acceptable limits.6 It was
found that only terpene type (X2) significantly affects
PDI, at a p-value =0.0188 in which a direct correlation
was detected between the PS and the PDI where the high
est PDI value was found in vesicles that had the largest PS,
and this is in agreement with Tawfik et al35. While regard
ing LPs formulations, PDI values ranged from 0.26±0.005
to 0.55±0.01 as displayed in Table 3 and Figure 2C.
Results revealed that only X2 (PC: SAA molar ratio) had
a significant positive effect on PDI with a p-value
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< 0.0001, which could be attributed to the high viscosity
of the dispersed phase at high PC concentration, which led
to particle aggregation and consequently increased the PS
and PDI and reduced homogenization of LPs dispersion.36

Effect of Formulation Variables on the ZP
ZP values of all the prepared TPs showed a negative
charge and ranged from −3.87±0.08 to −12.50±0.15mV,
as shown in Table 3 and Figure 1D. ANOVA results
showed that both X1 and X2 had a significant influence
on the ZP of theTPs with p values of < 0.0001 and 0.0001,
respectively. Using PC at a high concentration would
increase ZP values. It was assumed that in a medium of
low ionic strength, the polar head group is directed in
a way that the negatively charged phosphatidyl group is
oriented to the outside while the positively charged choline
group is placed to the inside leading to a net negative
charge on the surface.29 On the other hand, TPs fabricated
with fenchone showed higher ZP values than those fabri
cated with other terpenes, which may be due to its higher
EE%, as discussed before. It was previously reported that
increasing drug EE% results in increasing charges attained
by the vesicles due to its ionization in neutral or alkaline
pH into a negatively charged molecule.37
While all LPs formulae revealed positive surface
charge (32.10±0.70 to 45.35±0.15 mV) (Figure 2D), indi
cating good colloidal stability, the privileged positive
charge for these formulae enhanced the electrostatic inter
action between cationic LPs and the negatively charged
sialic acid residues of corneal mucins.8 Both independent
variables (X1 and X2) showed significant effects on ZP
with p values of 0.0003 and 0.001, respectively. Regarding
X1, it was found that DDAB formulae showed highest ZP
values than CTAB formulae revealing stabilizing effect of
cationic surfactant DDAB, and this result following
Hassan et al8. For X2, it was found that a high PC: SAA
molar ratio led to a higher positive charge and hence
higher ZP values.

Selection of the Optimized Formulae
To select the optimized formulae, certain conditions were
set in Design Expert® software version 11. These condi
tions favored nanovesicles with the highest EE%, ZP (as
absolute value), and lowest PS and PDI. The optimized
formula that met these criteria regarding TPs formulation
was composed of cineole as terpene type and had a PC
concentration of 3%. TPs optimized formula (TP4)
showed an EE% of 84.14±0.21%, a PS of 578.65±5.65
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nm, a PDI of 0.56±0.04, and a ZP of −12.5±0.30 mV. On
the other hand, LPs optimized formula, which was pro
posed to be prepared, was found to include PC: SAA
molar ratio of 1:1 and CTAB as SAA. LPs optimized
formula (LP1) revealed an EE% of 78.47±0.17%, a PS
of 102.41±3.39 nm, a PDI of 0.28±0.01, and a ZP of 32.50
±0.50 mV. To validate the experimental design, the pre
dicted and observed responses of TP4 and LP1 were
correlated and are shown in Table 2. A high correlation
was observed between the observed and predicted values.
Subsequently, TP4 and LP1 were selected as the optimized
formulae for further inspection.

Ex-vivo Studies

Table 4 Corneal Permeability Parameters of MOX After
Application of MOX Solution, TP4, and LP1
Corneal
Permeability
Parameters
Total amount of MOX
permeated per unit

MOX

TP4

LP1

67.93±1.95

151.77±2.75

541.94±3.04

11.32±0.32

25.29±0.45

90.32±0.50

1

2.23

7.97

Solution

area after 6 h (μg/cm2)
Jmax (μg/cm2/h)
ER

Note: Data are presented as mean ± SD (n=3).
Abbreviations: Jmax, permeation flux; ER, enhancement ratio; MOX, moxifloxacin
hydrochloride; TP, terpesome; LP, leciplex.

Ex-vivo Permeation Studies

CLSM

From Figure 3, it could be concluded that the quantity of
MOX permeated from LP1 was significantly (P≥0.5)
greater than that permeated from TP4 and MOX solution.
These results may be due to LPs’ cationic nature, which
enhances binding to the negatively charged mucus and
enhances the retention time.38 Similarly, PS affects the
drug permeation. The smaller the PS, the higher the inter
facial area accessible for drug exchange which facilitated
their delivery through the hydrated network of the corneal
stroma and accordingly enhances drug efficacy.39 The ER
was more than 7.97 times for LP1 and more than 2.23 for
TP4 compared to MOX solution, as illustrated in Table 4.
The significant higher permeability across the cornea from
LP1 and TP4 compared to MOX solution may be related
to the agglomeration of vesicles as a depot near the cornea
from which the drug is slowly delivered to the precorneal
area, as previously reported by Mudgil et al.40

CLSM was assessed to estimate the potency of infiltra
tion and fluorescence light intensity following ocular
delivery of fluoro-labeled TPs and LPs. Images gained
with CLSM (Figures 4 and 5) showed that the FDAloaded TPs and LPs exhibited deposition of fluorescence
in various eye layers. Scans were taken from the long
itudinal section that supplied information about the pene
tration depth of nanovesicles in corneal tissues. Both
nanovesicles showed homogeneous diffusion on the cor
neal tissues; however, by calculating the maximum inten
sity of fluorescent light, there was a significant (P≥0.5)
difference between the TPs and LPs as the average
intensity was 9119.81± 565.01 and 26804.23± 1615.27
for TPs and LPs, respectively. It is worth noting that
CLSM results supported ex-vivo permeation results.
Therefore, the previous findings could be justified to the
smaller PS of LPs compared to TPs that might aid the
nanovesicles to penetrate extensively in the corneal tis
sues as previously discussed.

Morphology
Morphological analysis of the selected LP formula is given
in Figure 6. The TEM image indicated that LP1 was
spherical and had a uniform distribution. The PS of the
LPs determined by Zetasizer was in good agreement with
TEM observations.

Stability Study
Figure 3 Cumulative amount of MOX permeated per unit area across excised cow
cornea via TP4 and LP1 relative to MOX solution.
Abbreviations: MOX, moxifloxacin hydrochloride; TP, terpesomes; LP, leciplex.
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LP1 was subjected to a short-term stability study for three
months. The visual inspection of the LP1 did not demon
strate any sedimentation or vesicles’ aggregation during
the storage period. The EE%, PS, PDI, and zeta potential
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Figure 4 A tile scan confocal laser microscope photomicrograph of longitudinal section in cow cornea treated with FDA loaded TPs I) Fluorescence light, II) transmitted
light and III) merge between fluorescence light and transmitted light.
Abbreviations: FDA, fluorescein diacetate; TPs, terpesomes.

Figure 5 A tile scan confocal laser microscope photomicrograph of longitudinal section in cow cornea treated with FDA loaded LPs I) Fluorescence light, II) transmitted
light and III) merge between fluorescence light and transmitted light.
Abbreviations: FDA, fluorescein diacetate; LPs, leciplex.

measurements of LP1 were 76.43±6.30%, 100.00±3.00
nm, 0.301±0.02, and 34.00±0.07 mV, respectively, which
showed insignificant variation from the freshly prepared
LPs (p>0.05). These findings revealed the physical stabi
lity of the formulated LP1, which may be related to the
presence of CTAB that gives a high positive charge on the
vesicle. The charge of the nanovesicles is a fundamental
property that can influence vesicular aspects. Electrostatic
repulsion can prohibit the mutual agglomeration, fusion of
vesicles, and promote vesicles’ stability.41

International Journal of Nanomedicine 2021:16

pH Measurement
pH values of LP1 were found to be 7.10 ± 0.12 implying
the convenience of LP1 for ocular utilization (pH of tears
=7.4).23

Evaluation of Mucoadhesion Properties of
Mucoadhesive Nanovesicles
The ZP of the mucin suspension was −9.77 mV ± 0.53
changed upon mixing with mucoadhesive leciplex (LP1).
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Figure 6 Morphology of the selected LPs.
Abbreviation: LPs, leciplex.

A positive value was obtained from the complexes formed
between mucin and LP1, where the negative charge of
the mucin would be neutralized with the positive charge
of the LP1 adhered on their surface. Takeuchi et al found
that the component adhesion might alter the surface prop
erties of the mucin if this component possesses
a mucoadhesive property.42 Mucoadhesive LP1 showed
a shift from negative mucin values to positive 10.66 ±
0.59 mV of mucin ZP value.

In-vivo Studies
MIC and Anti-Biofilm Assays
Highly virulent MRSA USA300 was used as the test
organism in all the experiments in this study. MOX LPs
and MOX solution were tested for their in-vitro anti
bacterial activity against MRSA USA300. Both MOX
LPs and MOX solution recorded the same MIC
(0.15625 μg/mL) with no effect of the LPs on the
antibacterial activity of MOX against MRSA USA300.
These results were in agreement with previous studies
that reported no negative effect of drug entrapment and
using LPs delivery system on the antimicrobial
activity.43 Biofilm formation by various pathogenic bac
teria plays an essential role in persistent infections and
increases the pathogen’s resistance to different antimi
crobial agents. Hence the ability of the antimicrobial
agent to inhibit and eradicate biofilm is essential for
the treatment of resistant pathogens rather than solely
on growth inhibition.25 Owing to the substantial role of
biofilm in aggravating Staphylococcal corneal
infections,2,44 we tested the effect of the LPs on the
anti-biofilm activity of MOX. We compared the antibiofilm activity of MOX LPs to that of MOX solution
at concentrations below the determined MIC (0.078125–
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0.00061 μg/mL). MOX LPs and MOX solution signifi
cantly inhibited MRSA USA300 biofilm formation at all
the tested concentrations (Two-way ANOVA, Dunnett’s
post-test, P < 0.0001). Although MOX LPs showed
higher biofilm inhibition activity than MOX solution,
there was no significant difference in the inhibition
potency against MRSA USA300 biofilm formation at
all the tested concentrations (Two-way ANOVA,
Sidak’s post-test, P < 0.05) (Figure 7A).
On the other hand, MOX LPs viewed significantly
higher biofilm eradication activity than MOX solution
against the previously established MRSA USA300 bio
film at all the tested concentrations (Two-way ANOVA,
Sidak’s post-test, P < 0.005) (Figure 7B). The biofilm
act as a protective barrier for the bacteria versus the
activity of the antibiotic.25 The superiority of MOX LPs
in eradicating the already established biofilm may be
attributed to the ability of the LPs to be adsorbed on
the surface of the biofilm, which may be due to the
strong affinity between the positively charged LPs and
the negatively charged bacterial cell membrane, thus
giving a higher chance to the released antibiotic to
penetrate the biofilm thus potentiating its antibacterial
activity.45 The smaller PS of the LPs might also permit
higher contact with the microbial surface and enhance
the antibacterial activity.

In-vivo Evaluation of MOX LPs Against MRSA
Corneal Infection in Mice
A murine MRSA corneal infection model was estab
lished to evaluate the in-vivo antibacterial activity of
the MOX LPs. The MOX LPs retained their antibacter
ial activity in-vivo with superior activity when com
pared to the MOX solution. Treatment with MOX LPs
or MOX solution significantly decreased the bacterial
number of MRSA USA300 compared to the negative
untreated control (Kruskal–Wallis test, Dunn’s post-test,
P<0.001) (Figure 8). MOX LPs showed significantly
higher antibacterial activity than MOX solution
(Kruskal–Wallis test, Dunn’s post-test, P<0.0001)
(Figure 8). The bacterial count recovered from the
MOX LPs and MOX solution treated eyes was 2.1 and
0.8 logs lower than that of the negative control eyes,
respectively. The bacterial count recovered from the
MOX LPs treated eyes was 1.3 logs lower than that of
the MOX solution treated eyes. The enhanced biofilm
eradication activity of MOX LPs might have played
a role in the superiority of MOX LPs in significantly
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Figure 7 The effect of MOX LPs and MOX solution against methicillin-resistant Staphylococcus aureus (MRSA USA300) biofilm. Results are expressed as mean biofilm
inhibition/eradication % ± standard error. ** & **Indicate that the difference is significant at p ≤0.0009 & p ≤0.005, respectively, (Two-way ANOVA, Sidak’s post-test). (A)
biofilm inhibition (B) biofilm eradication.
Abbreviations: MOX, moxifloxacin hydrochloride; LPs, leciplex.

reducing the bacterial load in the treated mice’s eyes.
The superiority of MOX LPs in the in-vivo corneal
infection model might also be attributed to the nature
of the LPs and smaller PS that contributed to better
corneal retention with more effective corneal contact
and enhanced MOX bioavailability. Our findings comply
with previous studies which have reported that drug
entrapment into nanoparticles enhanced drug pharmaco
kinetics in the aqueous humor,6,8,46 promoting the appli
cation of LPs as an effective ocular delivery system. It
is worth noting that the existence of CTAB enhanced the
antibacterial effect of MOX-loaded LPs compared to
MOX solution as it has an antibacterial effect, as

International Journal of Nanomedicine 2021:16

previously reported.47 Furthermore, histopathological
evaluation of ocular tissues was performed and showed
light microscopy inspection of stained sections. For
positive control group I: The covering epithelial cell
layer showed stratification while the underlying stroma
was intact; in addition, there was no histopathological
alteration as recorded in Figure 9. There was no histo
pathological alteration in the cornea, retina, or sclera for
groups II and III. The gained findings proposed that LPs
have a good safety profile, as there was no clear evi
dence of eye intolerability found in the in-vivo assess
ment; therefore, it might cause no ocular irritation in
clinical trials.
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Assessment of Serum Inflammatory
Biomarkers
Cytokines and other mediators play essential roles in eye
inflammation.48 In this study, we examined the secretion of
two inflammatory mediators, IL-1Beta and hs- CRP, in mice
treated with MOX-LPs and MOX solution to determine their
inflammation or irritation effect. It was found that mice with
MRSA corneal infection, which were treated with MOX LPs
and MOX solution, did not show any significant increase in
the serum level of these inflammatory cytokines (IL-1Beta
and hs-CRP) compared to a negative control (without treat
ment or infection) (Figure 10). These findings confirmed our
proposed formulation’s good safety profile, which is in good
agreement with the histopathological evaluation results.

Conclusion
Figure 8 Efficacy of MOX LPs and MOX solution in in-vivo murine model of MRSA
corneal infection. Sixteen male BALB/C mice were divided into two groups (n=8). The
right eyes were treated topically with either MOX LPs (0.5 %w/v) or MOX solution (0.5
%w/v). The left eye of each mouse did not receive any treatment and served as the
untreated negative control. The scatter plot shows the efficacy of MOX LPs/solution on
the bacterial load in the murine model of MRSA corneal infection. Results are expressed
as mean ± standard error. The dotted line represents the limit of detection of the viable
count (log 10 of 50 CFU = 1.699). **** & ***Indicate that the difference is significant at
p <0.0001 & p ≤0.0009, respectively, (Kruskal-Wallis test, Dunn’s post-test).
Abbreviation: MOX, moxifloxacin hydrochloride; LPs, leciplex.

In this study, MOX (a highly water-soluble drug) was success
fully encapsulated into different lipid-based vesicles, namely,
leciplex and terpesomes. Cationic leciplex achieved superior
ity compared to negatively charged vesicles (terpesomes) in
entrapment efficiency, particle size, zeta potential, and ex-vivo
studies. The results of ex-vivo and in-vivo studies point to the
success of positively charged vesicles in delivering

Figure 9 Photomicrographs showing histopathological sections (hematoxylin and eosin stained) of normal untreated mice eye (group I), mice eye treated with MOX solution
(group II) and mice eye treated with MOX LPs (group III) (A) illustrates histological structure of the cornea and (B) illustrates histological structure of the retina, choroid and sclera.
Abbreviations: MOX, moxifloxacin hydrochloride; LPs, leciplex.
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Figure 10 Assessment of serum level of inflammatory cytokines (IL-1Beta and hsCRP) in mice treated with MOX solution and MOX loaded LPs.
Abbreviations: MOX, moxifloxacin hydrochloride; IL-1Beta, interleukin 1-beta;
hs-CRP, high sensitive c-reactive protein; LPs, leciplex.

antimicrobial agents through complicated ocular anatomy.
Furthermore, the histopathological study confirmed the safety
of the formula and its suitability for ocular drug delivery. In
sum, all the data indicated that leciplex might be one of the
potential ocular delivery systems for hydrophilic drugs.
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